BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GSK3772701 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GSK3772701\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07545681-11207@assetmemo.bio
DTSTAMP:20261121T004118Z
DTSTART;VALUE=DATE:20271008
DTEND;VALUE=DATE:20271009
SUMMARY:GSK3772701: Phase 2 readout est. (NCT07545681)
DESCRIPTION:GSK3772701\, phase 2\, Malaria.\nStudy: A Phase 2A Study of a N
 ovel Antimalarial Pyrrolidinamide in Adult Patients With Uncomplicated P. 
 Falciparum Malaria\nEstimated primary completion: 8 October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/gsk3772701#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07545681
URL:https://assetmemo.bio/drug/gsk3772701#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
